Press Releases UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
13.22 ^USD	+0.08%		+3.77%	-11.87%

May. 14	Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating	MT
May. 13	Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights	May. 13	BU
UroGen Pharma to Participate at Upcoming Investor Conferences	May. 07	BU
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024	May. 06	AQ
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024	May. 06	AQ
UroGen Pharma Ltd. - New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival at 24 Months with JELMYTO across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy	May. 06	AQ
UroGen Pharma Ltd. - New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial	May. 06	AQ
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy	May. 05	BU
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024	May. 04	BU
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial	May. 04	BU
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024	May. 03	BU
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers	Apr. 17	BU
NORTHSTAR APPOINTS PETER PFREUNDSCHUH TO BOARD OF MANAGERS	Apr. 16	AQ
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer	Apr. 15	BU
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals	Apr. 03	BU
UroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102	Mar. 15	AQ
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102	Mar. 14	BU
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	Mar. 11	AQ
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 08	BU
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024	Mar. 04	BU
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference	Feb. 26	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Press Releases

Filters